Protagonist Therapeutics, Inc. Aktie News
78,51 $
4,33 %
gestern
Nasdaq,
28. Oktober, 21:05 Uhr
Index
Industrie
tracken
Protagonist Therapeutics, Inc. Aktie News
Positiv
Seeking Alpha
●
17 Tage alt
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its oral immunology drug icotrokinra and blockbuster potential of rusfertide for polycythemia vera, both with strong partnership structures. A JNJ acquisition could save milestone payments, secure future...
Positiv
The Motley Fool
●
18 Tage alt
Clinical-stage biotech Protagonist Therapeutics (PTGX 29.76%) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense takeover speculation.
Positiv
Reuters
●
19 Tage alt
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Positiv
WSJ
●
19 Tage alt
The two companies are already codeveloping a treatment for ulcerative colitis.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Douglas Tsao - H.C.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma Back to School Summit. I'm ...
Neutral
Accesswire
●
2 Monate alt
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Neutral
The Motley Fool
●
3 Monate alt
Protagonist (PTGX) Q2 Revenue Falls 26%
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
